Gennex Laboratories Limited (GENNEX.BO)
BSE · INR · Healthcare · Drug Manufacturers - Specialty & Generic
₹8.95 (+4.19%) as of
Key statistics
- Market cap
- 2.17B
- P/E (TTM)
- 11.62
- EPS (TTM)
- 0.77
- Dividend yield
- 0.00%
- 52-week range
- 7.05 – 17.25
- Beta
- 1.06
- Revenue (TTM)
- 1.78B
- Profit margin
- 11.56%
- Volume
- 239.01k
About Gennex Laboratories Limited
Gennex Laboratories Limited manufactures and sells bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, an expectorant used as a mucolyte; Methocarbamol for skeletal muscle relaxant; Fexofenadine Hcl for treating antihistamines; Phenazopyridine Hcl for the treatment of urinary tract analgesic; Fluconazole for antifungals; Melitracen Hcl for treating tricyclic antidepressant; Sertraline Hcl, a selective serotonin reuptake inhibitor; Chlorphenesin and Mephenesin; and Allopurinol, a xanthine oxidase inhibitor. It has operations in India, Algeria, Bangladesh, Barzil, Bolivia, Colombia, the Czech Republic, Egypt, El Salvador, Germany, Guatemala City, Mexico, Peru, Spain, Turkey, Thailand, the United Arab Emirates, and Vietnam. Gennex Laboratories Limited was formerly known as Prudential Pharmaceuticals Limited and changed its name to Gennex Laboratories Limited in September 2007. Gennex Laboratories Limited was incorporated in 1985 and is based in Hyderabad, India.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Hyderabad, India
- Employees
- 125
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.